- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
A Chemoresistance Signature to Predict FOLFIRINOX Sensitivity in Pancreatic Adenocarcinoma () - Dec 29, 2023 - Abstract #SSO2024SSO_412; In addition, our findings support targeting the G2M checkpoint and E2F pathways to potentially counteract FFX resistance in PDAC patients. Learning Objectives: Upon completion, participant will be able to understand the need for improving chemotherapy treatment strategies for pancreatic cancer.
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Highly Sensitive Low Input Methylated Digital Droplet PCR Assay for Pancreatic Adenocarcinoma Molecular Subtyping () - Dec 29, 2023 - Abstract #SSO2024SSO_408; ddPCR is a powerful, high sensitivity, lower cost technology offering clinical promise for the early detection and disease monitoring for many cancers, and it is already FDA approved for CML treatment response monitoring. Here we show our ability to predict subtype using only 14 nanograms of DNA on a ddPCR platform, >10 fold less required than Nanostring and >70 fold less than RNA sequencing.
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Combination of tumor and CAF subtypes better predict response to neoadjuvant therapy in pancreatic cancer () - Dec 29, 2023 - Abstract #SSO2024SSO_401; Better locoregional response to systemic therapy may lead to better overall survival in these subtypes. Molecular subtyping of PDAC for both the tumor and tumor microenvironment may be important steps in selecting first-line therapy for patients with this deadly disease.
- |||||||||| elimusertib (BAY 1895344) / Bayer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines (clinicaltrials.gov) - Dec 27, 2023 P1, N=90, Active, not recruiting, However, the effects on survival and safety outcomes could only be speculated, and further studies are needed because of the sample size, the follow-up for the OS evaluation, and the non-uniformity in all the variables considered in the two groups. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||||||||| 5-fluorouracil / Generic mfg.
Journal: 5-Fluorouracil-associated severe hypertriglyceridaemia with positive rechallenge. (Pubmed Central) - Dec 24, 2023 We here report the case of a patient who developed 5-FU-associated grade 4 HTG with TG level raising up to 37.1?mmol/L (3286?mg/dL) occurring after the ninth cycle of adjuvant FOLFOX (Fluorouracil and Oxaliplatin) chemotherapy...Chemotherapy was therefore permanently stopped. Approximately 8 weeks after chemotherapy discontinuation, TG fell back to range at 2.1?mmol/L (189?mg/dL) allowing interruption of fenofibrate without HTG recurrence at 3 months.
- |||||||||| leucovorin calcium / Generic mfg.
Journal: Cerebral folate deficiency: a treatable cause of late deterioration in epilepsy with developmental delay. (Pubmed Central) - Dec 23, 2023 Following antiseizure medication adjustment and treatment with folinic acid, she stabilised with improved seizure control and limited improvement in language and motor function; she has remained neurologically stable for more than a decade...Metabolic conditions are less well recognised in adults and can be under-diagnosed. They are potentially treatable and should be considered even in the presence of another cause, particularly when the presentation is not fully compatible.
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: Precision medicine for KRAS wild-type pancreatic adenocarcinomas. (Pubmed Central) - Dec 22, 2023 KRAS patients display distinct disease characteristics and outcomes with prolonged overall survival. KRAS patients also harbor more actionable molecular alterations, leading to higher survival rates after receiving molecularly matched treatments.
- |||||||||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial primary completion date, Metastases: NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer (clinicaltrials.gov) - Dec 21, 2023 P2, N=44, Recruiting, Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024 Trial primary completion date: Nov 2023 --> May 2024
- |||||||||| Graspa (eryaspase) / PHAXIAM Therap
Trial completion date: Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Dec 20, 2023 P1, N=19, Active, not recruiting, A randomized or prospective trial will be required to further prove these data and explore its potentiality, especially if compared to conventional treatment. Trial completion date: Dec 2023 --> Jul 2024
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Immuno-molecular modulation in pancreatic cancer following isotoxic high-dose stereotactic body radiotherapy (iHD-SBRT). (Teun - Hilton Antwerp Old Town) - Dec 19, 2023 - Abstract #BWG2024BWG_177; Methods Paraffin-embedded residual tumoral tissues of 50 localized PDAC resected between 2011 and 2020 were used: seventeen patients had surgery first, seventeen received an induction chemotherapy with FOLFIRINOX (FFX) only and sixteen with FFX followed by an iHD-SBRT designed to individually maximize the dose prescribed to the tumor and vessels interfaces up to Dmax(0.5cc)<lt;53Gy in 5 fractions...Despite an increase in collagen deposit, the global lymphocyte infiltration is preserved after iHD-SBRT. We also identified several increased pro-tumoral cells and pathways after iHD-SBRT that could improve the development of better-oriented combination trials involving high-dose SBRT.
- |||||||||| Avastin (bevacizumab) / Roche
Biomarker, Trial completion date, Trial primary completion date: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - Dec 19, 2023 P3, N=3610, Active, not recruiting, Considering that sleep disturbance is a modifiable factor that can impact immune regulation, it is essential to prioritise the management of sleep disturbances in CRC patients receiving FOLFOX chemotherapy. Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2023 --> Mar 2024
- |||||||||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment closed, Trial completion date, Trial primary completion date: GIANT: Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread (clinicaltrials.gov) - Dec 19, 2023 P2, N=176, Active, not recruiting, Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2023 --> Mar 2024 Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025
- |||||||||| 5-fluorouracil / Generic mfg.
Journal, Surgery, Metastases: Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy. (Pubmed Central) - Dec 18, 2023 Resection of LAPC following chemo(radio)therapy is infrequently performed in the Netherlands, albeit with acceptable morbidity, mortality, and OS. Given these findings, a structured nationwide approach involving international centers of excellence would be needed to improve selection of patients with LAPC for surgical resection following induction therapy.
- |||||||||| lunresertib (RP-6306) / Repare Therap
Trial completion date, Trial primary completion date: RP-6306 in Patients With Advanced Cancer (clinicaltrials.gov) - Dec 15, 2023 P2, N=78, Recruiting,
- |||||||||| Yutuo (zimberelimab) / Arcus Biosci, Gilead, domvanalimab (AB154) / Arcus Biosci, Gilead
Trial completion date, Trial primary completion date: STAR-221: A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (clinicaltrials.gov) - Dec 15, 2023 P3, N=970, Recruiting,
|